This invention relates to a process for the preparation of triazine carbamates by reacting a mixture of an aminotriazine A having at least two amino groups per molecule, an organic carbonate C, and a base B selected from the group consisting of alkoxides, and arylalkoxides of metals M, which may be alkali or earth alkali metals, and a solvent S which is a monohydric alcohol solvent R.sup.2OH or a mixture of solvents that comprises a monohydric alcohol R.sup.2OH, and a monohydric alcohol R.sup.3OH, or a mixture of solvents that comprises a monohydric alcohol R.sup.2OH with a further solvent selected from the group consisting of ether, alcohol, and hydrocarbon solvents, and adding to the products of the said reaction, an acid or a solution of an acid in a solvent.

Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer. ##STR00001##

Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer. ##STR00001##

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Compositions and methods related to conducting polymeric compositions that can be used for the storage of electrical energy are generally provided. In some embodiments, the composition comprises redox active polymers comprising an electrophilic nitrogen containing heterocycle and an electron rich aromatic compound. In some embodiments, the composition comprises a triazine-based polymer. The electroactive polymers may be formed, in some cases, by polymerizing an electrophilic nitrogen containing heterocycle-based unit with an electron rich aromatic compound in the presence of heat and an acid-based catalyst. The resulting electroactive polymers may be suitable as polymer films for use as electrodes in energy storage devices. The polymer films disposed as electrodes can improve the energy density of such devices.

The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies. ##STR00001##

The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies. ##STR00001##

The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.

##STR00001##

The application is directed to compounds of formula (I): and their salts and solvates, wherein R.sup.1, R.sup.2, R.sup.3, A.sup.1, A.sup.2, A.sup.3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.

##STR00001##